VERTEX PHARMACEUTICALS INC
NASDAQ: VRTX (Vertex Pharmaceuticals Incorpor)
Kemas kini terakhir: 9 jam lalu463.48
-7.39 (-1.57%)
| Penutupan Terdahulu | 470.87 |
| Buka | 469.85 |
| Jumlah Dagangan | 2,081,183 |
| Purata Dagangan (3B) | 1,403,291 |
| Modal Pasaran | 118,831,947,776 |
| Harga / Pendapatan (P/E TTM) | 32.59 |
| Harga / Pendapatan (P/E Ke hadapan) | 24.10 |
| Harga / Jualan (P/S) | 10.37 |
| Harga / Buku (P/B) | 6.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Feb 2026 |
| Margin Keuntungan | -8.91% |
| Margin Operasi (TTM) | 37.22% |
| EPS Cair (TTM) | -3.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -41.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.00% |
| Nisbah Semasa (MRQ) | 2.65 |
| Aliran Tunai Operasi (OCF TTM) | -980.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.63 B |
| Pulangan Atas Aset (ROA TTM) | 11.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Vertex Pharmaceuticals Incorpor | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.00 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 0.15% |
| % Dimiliki oleh Institusi | 97.64% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 606.00 (Barclays, 30.75%) | Beli |
| Median | 545.50 (17.70%) | |
| Rendah | 515.00 (Wells Fargo, 11.12%) | Beli |
| Purata | 547.38 (18.10%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 464.85 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 28 Jan 2026 | 606.00 (30.75%) | Beli | 477.91 |
| UBS | 26 Jan 2026 | 545.00 (17.59%) | Beli | 476.84 |
| 07 Jan 2026 | 535.00 (15.43%) | Beli | 484.15 | |
| Evercore ISI Group | 23 Jan 2026 | 530.00 (14.35%) | Beli | 468.41 |
| RBC Capital | 22 Jan 2026 | 546.00 (17.80%) | Beli | 467.35 |
| Wolfe Research | 06 Jan 2026 | 548.00 (18.24%) | Beli | 468.38 |
| Leerink Partners | 29 Dec 2025 | 525.00 (13.27%) | Beli | 459.78 |
| Wells Fargo | 10 Dec 2025 | 515.00 (11.12%) | Beli | 444.64 |
| Morgan Stanley | 05 Dec 2025 | 564.00 (21.69%) | Beli | 455.48 |
| 03 Dec 2025 | 516.00 (11.33%) | Beli | 463.13 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |